- In September 2024, the U.S. FDA cleared the FG-001 Platelet Rich Plasma (PRP) Device which is designed to be used for the safe and rapid preparation of platelet rich plasma (PRP) from a small sample of blood at the patient’s point of care.
- In August 2024, the U.S. FDA approved Illuminate PRP, designed for the swift and safe preparation of autologous platelet-rich plasma (PRP) from a minor peripheral blood sample, directly at the patient's point-of-care.
- In April 2024, The U.S. FDA has approved the Thrombinator System for use with Arthrex PRP Systems. These include the Arthrex Angel concentrated Platelet Rich Plasma (cPRP) System, the Arthrex Double Syringe (ACP) System, and the Arthrex ACP Max Platelet-Rich Plasma (PRP) System.
- In January 2024, Arthrex Demonstrated to the media the use of the ACP Max system for creating a highly concentrated platelet-rich plasma (PRP) with low neutrophil content.
